Preclinical News and Research

RSS

New approach could be used to treat Duchenne muscular dystrophy

Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and Center for Duchenne Muscular Dystrophy at UCLA have developed a new approach that could eventually be used to treat Duchenne muscular dystrophy.

14 Feb 2016

Astrocytes implicated in preclinical AD

Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows.

12 Feb 2016

MGH study reveals effects of obesity on pancreatic and breast cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.

12 Feb 2016

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

Lung cancer is one of the most prevalent types of cancer, with more than 20,000 new cases diagnosed each year in Spain. Lung adenocarcinomas carrying oncogenic KRAS, the engine driving these tumours in 30% of cases, constitute the most aggressive sub-type because, unlike other types of lung cancer, there are no targeted therapies beyond the standard cisplatin-based treatment.

12 Feb 2016

Study identifies FGF21 protein as potential therapeutic agent for cardiovascular diseases, type 2 diabetes

New research on the blood lipid-lowering protein FGF21 shows how it redistributes fatty acids by two distinct mechanisms. The discovery could lead to improved pharmaceutical treatment for type 2 diabetes and other obesity-related diseases.

11 Feb 2016

Unlocking intrinsically disordered proteins: an interview with Peter Wright

I'm a professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute. I have been performing NMR research on proteins for nearly 40 years.

From Bruker BioSpin Group 11 Feb 2016

UC San Diego School of Medicine launches new NAFLD Research Center

Roughly one-quarter of all Americans - an estimated 100 million adults and children - have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure.

9 Feb 2016

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report.

9 Feb 2016

Duchenne muscular dystrophy: direct effect on muscle stem cells? An interview with Dr Rudnicki

For twenty years, it has been understood that dystrophin is expressed in differentiated muscle fibers where it is part of a protein complex that crosses the membrane and connects the extracellular matrix to the actin network inside the cell to provide structural integrity.

5 Feb 2016

UTHealth researchers demonstrate new way to reduce preterm birth

Using nanoparticles to engineer a special drug, a team of researchers from McGovern Medical School at The University of Texas Health Science Center at Houston has demonstrated in pre-clinical trials a new way to both reduce preterm birth and avoid the risks of medication in pregnancy to unborn babies.

5 Feb 2016

Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on Lamellasome™ technology, is pleased to announce the publication of a paper in the Supportive Care in Cancer Journal.

5 Feb 2016

Noninvasive FMRI may help evaluate effectiveness of new pain medications

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.

4 Feb 2016

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Interview conducted with Professor Björn Wängler, Professor for Molecular Imaging and Radiochemistry from Heidelberg University.

From Bruker BioSpin Group 4 Feb 2016

Researchers identify new targets that may help prevent and cure colon cancer

When the audio on your television set or smart phone is too loud, you simply turn down the volume. What if we could do the same for the signaling in our bodies that essentially causes normal cells to turn cancerous? New discoveries by researchers at the Stephenson Cancer Center at the University of Oklahoma may point to new ways to do just that.

3 Feb 2016

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible.

3 Feb 2016

Genetic profiling ‘feasible’ for paediatric cancer patients

Research published in JAMA Oncology demonstrates that tumour and germline molecular profiling is feasible in paediatric cancer patients and can have actionable findings.

2 Feb 2016

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

1 Feb 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).

29 Jan 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Preclinical News and Research

New approach could be used to treat Duchenne muscular dystrophy

Astrocytes implicated in preclinical AD

MGH study reveals effects of obesity on pancreatic and breast cancer

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

Study identifies FGF21 protein as potential therapeutic agent for cardiovascular diseases, type 2 diabetes

Unlocking intrinsically disordered proteins: an interview with Peter Wright

UC San Diego School of Medicine launches new NAFLD Research Center

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Duchenne muscular dystrophy: direct effect on muscle stem cells? An interview with Dr Rudnicki

UTHealth researchers demonstrate new way to reduce preterm birth

Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Noninvasive FMRI may help evaluate effectiveness of new pain medications

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Researchers identify new targets that may help prevent and cure colon cancer

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Genetic profiling ‘feasible’ for paediatric cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics